Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR) announced its participation in multiple investor conferences in March 2024, including TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, Jefferies Biotech on the Bay Summit, and Barclays Global Healthcare Conference. Live webcasts and replays of the presentations will be available on the company's website.
02/28/2024 - 04:01 PM
PASADENA, Calif. --(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:
TD Cowen 44th Annual Health Care Conference
Date: Wednesday, March 6, 2024
Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT
Location: Boston
Leerink Partners Global Biopharma Conference
Date: Tuesday, March 12, 2024
Presentation Date/Time: Wednesday, March 13, 2024, 9:20 a.m. ET / 6:20 a.m. PT
Location: Miami
Jefferies Biotech on the Bay Summit
Date: Wednesday, March 13, 2024
Location: Miami
Barclays Global Healthcare Conference
Date: Thursday, March 14, 2024
Presentation Time: 11:15 a.m. ET / 8:15 a.m. PT
Location: Miami
Live webcasts of the Cowen, Leerink and Barclays presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com . Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228121602/en/
Charles Liles
cliles@xencor.com
(626) 737-8118
Source: Xencor, Inc.
When will Xencor participate in the TD Cowen 44th Annual Health Care Conference?
Xencor will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 12:50 p.m. ET / 9:50 a.m. PT.
Where will the Leerink Partners Global Biopharma Conference take place?
The Leerink Partners Global Biopharma Conference will be held in Miami on Tuesday, March 12, 2024, with the presentation on Wednesday, March 13, 2024, at 9:20 a.m. ET / 6:20 a.m. PT.
How can investors access the webcasts of the Cowen, Leerink, and Barclays presentations?
Investors can access the live webcasts of the Cowen, Leerink, and Barclays presentations under 'Events & Presentations' in the Investors section of Xencor's website at www.xencor.com.
For how long will replays of the events be available on the Xencor website?
Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
XNCR Rankings
#4337 Ranked by Stock Gains
XNCR Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Monrovia
About XNCR
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product